PD153035 (Synonyms: SU-5271; AG1517; ZM 252868)

目录号: HY-14346 纯度: 98.83%: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

PD153035 (SU-5271; AG1517; ZM 252868) 是有效地 EGFR 抑制剂，K_i 和 IC₅₀ 值分别为6和25 pM。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

PD153035 Chemical Structure

CAS No. : 153436-54-5

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥550	In-stock
5 mg	￥500	In-stock
10 mg	￥663	In-stock
50 mg	￥2480	In-stock
100 mg		询价
200 mg		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of PD153035:

PD153035 Hydrochloride In-stock

MCE 顾客使用本产品发表的 8 篇科研文献

PD153035 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 EGFR 亚型特异性产品:

查看所有亚型

EGFR/ErbB1/HER1 ErbB2/HER2 ErbB3/HER3 ErbB4/HER4

生物活性
实验参考方法
纯度 & 产品资料
参考文献

生物活性

PD153035 (SU-5271; AG1517; ZM 252868) is a potent EGFR inhibitor with K_i and IC₅₀ of 6 and 25 pM, respectively.

IC₅₀ & Target^[1]

EGFR

6 pM (Ki)

EGFR

25 pM (IC₅₀)

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A-431	IC₅₀	0.025 nM Compound: 14	Inhibition of the phosphorylation of a random polyglutamic acid/tyrosine copolymer by human epidermal growth factor receptor(EGFR) prepared from human A431 carcinoma cells Inhibition of the phosphorylation of a random polyglutamic acid/tyrosine copolymer by human epidermal growth factor receptor(EGFR) prepared from human A431 carcinoma cells	[PMID: 9154973]
A-431	IC₅₀	0.025 nM Compound: 32	Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles	[PMID: 8568816]
A-431	IC₅₀	0.029 nM Compound: 3	Evaluation of inhibitory activity against phospholipase C-gamma1 phosphorylation by Epidermal growth factor receptor enzyme isolated from A431 cells. Evaluation of inhibitory activity against phospholipase C-gamma1 phosphorylation by Epidermal growth factor receptor enzyme isolated from A431 cells.	[PMID: 7658435]
A-431	IC₅₀	0.2 μM Compound: 21, PD153035	Inhibition of EGFR in human A431 cells assessed as inhibition of EGF-induced tyrosine phosphorylation incubated for 60 mins prior to EGF-activation measured 10 mins by ELISA Inhibition of EGFR in human A431 cells assessed as inhibition of EGF-induced tyrosine phosphorylation incubated for 60 mins prior to EGF-activation measured 10 mins by ELISA	[PMID: 23434139]
A-431	IC₅₀	0.2 μM Compound: 49, PD-153035	Inhibition of EGFR phosphorylation in human A431 cells after 10 mins by FLISA Inhibition of EGFR phosphorylation in human A431 cells after 10 mins by FLISA	[PMID: 20403700]
A-431	IC₅₀	0.2 μM Compound: 20, PD-153035	Inhibition of EGF-induced EGFR autophosphorylation in human A431 cells incubated for 60 mins prior to EGF-induction measured after 10 mins by phosphotyrosine ELISA Inhibition of EGF-induced EGFR autophosphorylation in human A431 cells incubated for 60 mins prior to EGF-induction measured after 10 mins by phosphotyrosine ELISA	[PMID: 22370340]
A-431	IC₅₀	0.2 μM Compound: 17, PD-153035	Inhibition of EGFR in human A431 cells by phosphotyrosine ELISA Inhibition of EGFR in human A431 cells by phosphotyrosine ELISA	[PMID: 19748785]
A-431	IC₅₀	0.23 μM Compound: 20, PD-153035	Inhibition of EGFR tyrosine kinase activity in EGF-stimulated human A431 cells after 60 mins by ELISA Inhibition of EGFR tyrosine kinase activity in EGF-stimulated human A431 cells after 60 mins by ELISA	[PMID: 22204741]
A-431	IC₅₀	0.23 μM Compound: 18, PD-153035	Inhibition of EGFR in human A431 cells pretreated for 60 mins measured after 1 hr by ELISA Inhibition of EGFR in human A431 cells pretreated for 60 mins measured after 1 hr by ELISA	[PMID: 22739090]
A-431	IC₅₀	0.23 μM Compound: 25, PD153035	Inhibition of EGF-induced EGFR phosphorylation in human A431 cells overexpressing EGFR pretreated for 60 mins prior to EGF addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis Inhibition of EGF-induced EGFR phosphorylation in human A431 cells overexpressing EGFR pretreated for 60 mins prior to EGF addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis	[PMID: 23375090]
A-431	IC₅₀	0.23 μM Compound: 13, PD-153035	Inhibition of EGFR in human A431 cells by phosphotyrosine cell-based ELISA Inhibition of EGFR in human A431 cells by phosphotyrosine cell-based ELISA	[PMID: 20092323]
A-431	IC₅₀	12.6 μM Compound: 25, PD153035	Cytotoxicity against human A431 cells overexpressing EGFR assessed as inhibition of cell proliferation treated for 12 hrs measured after 36 hrs by CYQUANT dye based assay Cytotoxicity against human A431 cells overexpressing EGFR assessed as inhibition of cell proliferation treated for 12 hrs measured after 36 hrs by CYQUANT dye based assay	[PMID: 23375090]
A-431	IC₅₀	12.6 μM Compound: 20, PD-153035	Cytotoxicity against human A431 cells overexpressing EGFR incubated for 12 hrs measured after 36 hrs by CYQUANT assay Cytotoxicity against human A431 cells overexpressing EGFR incubated for 12 hrs measured after 36 hrs by CYQUANT assay	[PMID: 22370340]
A-431	IC₅₀	12.6 μM Compound: 17, PD-153035	Cytotoxicity against human A431 cells after 48 hrs by CYQUANT cell proliferation assay Cytotoxicity against human A431 cells after 48 hrs by CYQUANT cell proliferation assay	[PMID: 19748785]
A-431	IC₅₀	2.26 μg/mL Compound: PD-153035	Antiproliferative activity against human A431 cells after 24 to 48 hrs by WST1 assay Antiproliferative activity against human A431 cells after 24 to 48 hrs by WST1 assay	[PMID: 22901387]
A-431	IC₅₀	26.29 μM Compound: 1, PD-153035	Reversibility of antiproliferative activity against human A431 cells after recovery for 68 hrs by MTT assay Reversibility of antiproliferative activity against human A431 cells after recovery for 68 hrs by MTT assay	[PMID: 17154492]
A-431	IC₅₀	4.4 μM Compound: PD153035	Antiproliferative activity against human A431 cells after 72 hrs by MTT assay Antiproliferative activity against human A431 cells after 72 hrs by MTT assay	[PMID: 23900004]
A-431	IC₅₀	4.4 μM Compound: PD-153035	Cytotoxicity against human A431 cells after 72 hrs by MTT assay Cytotoxicity against human A431 cells after 72 hrs by MTT assay	[PMID: 20095624]
A-431	IC₅₀	8.31 μM Compound: 1, PD-153035	Antiproliferative activity against human A431 cells after 72 hrs by MTT assay Antiproliferative activity against human A431 cells after 72 hrs by MTT assay	[PMID: 17154492]
A549	IC₅₀	8.13 μg/mL Compound: PD-153035	Antiproliferative activity against human A549 cells after 24 to 48 hrs by WST1 assay Antiproliferative activity against human A549 cells after 24 to 48 hrs by WST1 assay	[PMID: 22901387]
B16-F10	IC₅₀	1.74 μg/mL Compound: PD-153035	Antiproliferative activity against mouse B16F10 cells after 24 to 48 hrs by WST1 assay Antiproliferative activity against mouse B16F10 cells after 24 to 48 hrs by WST1 assay	[PMID: 22901387]
Bcap37	IC₅₀	13.7 μM Compound: PD-153035	Growth inhibition of human Bcap37 cells after 72 hrs by MTT assay Growth inhibition of human Bcap37 cells after 72 hrs by MTT assay	[PMID: 17681471]
Bcap37	IC₅₀	15.7 μM Compound: PD153035	Growth inhibition of human Bcap37 cells after 72 hrs by MTT assay Growth inhibition of human Bcap37 cells after 72 hrs by MTT assay	[PMID: 23811258]
Bcap37	IC₅₀	15.7 μM Compound: PD153035	Antiproliferative activity against human Bcap37 cells by MTT assay Antiproliferative activity against human Bcap37 cells by MTT assay	[PMID: 24583357]
Bcap37	IC₅₀	8.9 μM Compound: PD-153035	Antitumor activity against human Bcap37 cells by MTT method Antitumor activity against human Bcap37 cells by MTT method	[PMID: 17317179]
BGC-823	IC₅₀	14.4 μM Compound: PD153035	Growth inhibition of human BGC823 cells after 72 hrs by MTT assay Growth inhibition of human BGC823 cells after 72 hrs by MTT assay	[PMID: 23811258]
BGC-823	IC₅₀	14.4 μM Compound: PD153035	Antiproliferative activity against human BGC823 cells by MTT assay Antiproliferative activity against human BGC823 cells by MTT assay	[PMID: 24583357]
BGC-823	IC₅₀	16.8 μM Compound: PD-153035	Growth inhibition of human BGC823 cells after 72 hrs by MTT assay Growth inhibition of human BGC823 cells after 72 hrs by MTT assay	[PMID: 17681471]
BGC-823	IC₅₀	6.9 μM Compound: PD-153035	Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay	[PMID: 20817326]
BGC-823	IC₅₀	6.9 μM Compound: PD-153035	Antitumor activity against human BGC823 cells by MTT method Antitumor activity against human BGC823 cells by MTT method	[PMID: 17317179]
EA.hy 926	IC₅₀	7.1 μM Compound: 3a, PD-153035	Antiproliferative activity against human EAhy926 cells at 10 uM after 72 hrs by MTS assay Antiproliferative activity against human EAhy926 cells at 10 uM after 72 hrs by MTS assay	[PMID: 21353546]
HEK293	IC₅₀	260 nM Compound: 13; CA336	Inhibition of tracer 5 binding to human N-terminal nano luciferase-fused GAK expressed in HEK293 cells measured after 2 hrs by nanoBRET assay Inhibition of tracer 5 binding to human N-terminal nano luciferase-fused GAK expressed in HEK293 cells measured after 2 hrs by nanoBRET assay	[PMID: 30973735]
HeLa	IC₅₀	> 10 μM Compound: PD153035	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 23900004]
HT-29	IC₅₀	> 10 μM Compound: PD153035	Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 23900004]
HT-29	IC₅₀	10.1 μM Compound: 3a, PD-153035	Antiproliferative activity against human HT-29 cells at 10 uM after 72 hrs by MTS assay Antiproliferative activity against human HT-29 cells at 10 uM after 72 hrs by MTS assay	[PMID: 21353546]
HT-29	IC₅₀	10.1 μM Compound: 1a, PD-153035	Antiproliferative activity against human HT-29 cells after 72 hrs by MTS assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTS assay	[PMID: 21033670]
HUVEC	IC₅₀	4.06 μM Compound: PD153035	Antiproliferative activity against HUVEC after 72 hrs by MTT assay Antiproliferative activity against HUVEC after 72 hrs by MTT assay	[PMID: 23900004]
MCF7	IC₅₀	3.21 μg/mL Compound: PD-153035	Antiproliferative activity against human MCF7 cells after 24 to 48 hrs by WST1 assay Antiproliferative activity against human MCF7 cells after 24 to 48 hrs by WST1 assay	[PMID: 22901387]
MCF7	IC₅₀	4.7 μM Compound: 3a, PD-153035	Antiproliferative activity against human MCF7 cells at 10 uM after 72 hrs by MTS assay Antiproliferative activity against human MCF7 cells at 10 uM after 72 hrs by MTS assay	[PMID: 21353546]
MCF7	IC₅₀	4.7 μM Compound: 1a, PD-153035	Antiproliferative activity against human MCF7 cells after 72 hrs by MTS assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTS assay	[PMID: 21033670]
MDA-MB-468	IC₅₀	0.68 μM Compound: 16; PD153036	Inhibition of EGFR in human MDA-MB-468 cells assessed as reduction in cell proliferation incubated for 72 hrs by Coulter counter method Inhibition of EGFR in human MDA-MB-468 cells assessed as reduction in cell proliferation incubated for 72 hrs by Coulter counter method	[PMID: 30878832]
MDCK-II	IC₅₀	1.73 μM Compound: 43, PD153035	Inhibition of human BCRP expressed in MDCK2 cells assessed as Hoechst 33342 accumulation treated 30 mins before Hoechst 33342 addition measured up to 120 mins by fluorescence assay Inhibition of human BCRP expressed in MDCK2 cells assessed as Hoechst 33342 accumulation treated 30 mins before Hoechst 33342 addition measured up to 120 mins by fluorescence assay	[PMID: 24184213]
MDCK-II	IC₅₀	2.32 μM Compound: 43, PD153035	Inhibition of human BCRP expressed in MDCK2 cells assessed as pheophorbide A accumulation treated 30 mins before pheophorbide A addition measured up to 120 mins by flow cytometry Inhibition of human BCRP expressed in MDCK2 cells assessed as pheophorbide A accumulation treated 30 mins before pheophorbide A addition measured up to 120 mins by flow cytometry	[PMID: 24184213]
NIH3T3	IC₅₀	> 10 μM Compound: PD153035	Antiproliferative activity against mouse NIH/3T3 cells after 72 hrs by MTT assay Antiproliferative activity against mouse NIH/3T3 cells after 72 hrs by MTT assay	[PMID: 23900004]
NIH3T3	IC₅₀	> 10 μM Compound: PD-153035	Cytotoxicity against mouse NIH/3T3 cells after 72 hrs by MTT assay Cytotoxicity against mouse NIH/3T3 cells after 72 hrs by MTT assay	[PMID: 20095624]
PC-3	IC₅₀	> 10 μM Compound: 1a, PD-153035	Antiproliferative activity against human PC3 cells after 72 hrs by MTS assay Antiproliferative activity against human PC3 cells after 72 hrs by MTS assay	[PMID: 21033670]
PC-3	IC₅₀	13.7 μM Compound: PD-153035	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 20817326]
PC-3	IC₅₀	13.7 μM Compound: PD-153035	Antitumor activity against human PC3 cells by MTT method Antitumor activity against human PC3 cells by MTT method	[PMID: 17317179]
PC-3	IC₅₀	8.3 μM Compound: PD153035	Growth inhibition of human PC3 cells after 72 hrs by MTT assay Growth inhibition of human PC3 cells after 72 hrs by MTT assay	[PMID: 23811258]
PC-3	IC₅₀	8.3 μM Compound: PD153035	Antiproliferative activity against human PC3 cells by MTT assay Antiproliferative activity against human PC3 cells by MTT assay	[PMID: 24583357]
PC-3	IC₅₀	8.9 μM Compound: PD-153035	Growth inhibition of human PC3 cells after 72 hrs by MTT assay Growth inhibition of human PC3 cells after 72 hrs by MTT assay	[PMID: 17681471]

体外研究
(In Vitro)

PD153035 (SU 5271) inhibits EGF-stimulated receptor autophosphorylation in A431 human epidermoid carcinoma cells, with an IC₅₀ of 14 nM^[1]. PD153035 (SU 5271) has little effect on PDGFR, FGFR, CSF-1 receptor, the insulin receptor, or on src tyrosine kinases at concentrations as high as 50 μM. PD153035 (SU 5271) rapidly suppresses autophosphorylation of the EGF receptor at low nanomolar concentrations in fibroblasts or in human epidermoid carcinoma cells and selectively blocks EGF-mediated cellular processes including mitogenesis, early gene expression, and oncogenic transformation^[2]. PD153035 (SU 5271) causes a dose-dependent growth inhibition of EGF receptor-positive cell lines, beginning at less than micromolar concentrations, and the IC₅₀ is less than 1 pM in most cases^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

PD153035 (SU 5271) levels in the plasma and tumor rise to 50 and 22 μM within 15 minutes following a single i.p. dose of 80 mg/kg. While the plasma levels of PD153035 (SU 5271) falls below 1 μM by 3 hours, in the tumors it remains at micromolar concentrations for at least 12 hours. The tyrosine phosphorylation of the EGF receptor is rapidly suppressed by 80-90% in the tumors^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

360.21

Formula

C₁₆H₁₄BrN₃O₂

CAS 号

153436-54-5

性状

固体

颜色

White to off-white

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

溶解性数据

细胞实验：

DMSO 中的溶解度 : 33.33 mg/mL (92.53 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.7762 mL	13.8808 mL	27.7616 mL
5 mM	0.5552 mL	2.7762 mL	5.5523 mL
10 mM	0.2776 mL	1.3881 mL	2.7762 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C储存时，请在2年内使用， -20°C储存时，请在1年内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (6.94 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 98.83%

选择批次：

Data Sheet (630 KB) SDS (393 KB)

COA (204 KB) LCMS (93 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Bridges AJ, et al. Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J Med Chem. 1996 Jan 5;39(1):267-76. [Content Brief]

[2]. Fry DW, et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science. 1994 Aug 19;265(5175):1093-5. [Content Brief]

[3]. Bos M, et al. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptoractivation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin Cancer Res. 1997 Nov;3(11):2099-106. [Content Brief]

[4]. Kunkel MW, et al. Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude mice. Invest New Drugs. 1996;13(4):295-302. [Content Brief]

Cell Assay ^[3]	Different EGF receptor-overexpressing cell lines (A43 1, Difi, MDA-MB-468, MDA-MB-231, DU145, SiHa, C4i, and MEl 80) are treated with PD153035 at increasing concentrations of 0.125-2.5 p.M. Growth inhibitory effect in monolayer cell culture is assessed^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[3]	Mice: Mice are injected with PD153035 (SU 5271) (80 mg/kg) or vehicle and rumors are excised at 20 minutes and 180 minutes and extracts are prepared. Two mice are used for each time point and the experiment is repeated four times. Within each of the four experiments ANOVA is used to compare the inhibition by PD153035 (SU 5271) of the EGF-stimulation^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Bridges AJ, et al. Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J Med Chem. 1996 Jan 5;39(1):267-76. [Content Brief] [2]. Fry DW, et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science. 1994 Aug 19;265(5175):1093-5. [Content Brief] [3]. Bos M, et al. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptoractivation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin Cancer Res. 1997 Nov;3(11):2099-106. [Content Brief] [4]. Kunkel MW, et al. Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude mice. Invest New Drugs. 1996;13(4):295-302. [Content Brief]

PD153035 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.7762 mL	13.8808 mL	27.7616 mL	69.4040 mL
	5 mM	0.5552 mL	2.7762 mL	5.5523 mL	13.8808 mL
	10 mM	0.2776 mL	1.3881 mL	2.7762 mL	6.9404 mL
	15 mM	0.1851 mL	0.9254 mL	1.8508 mL	4.6269 mL
	20 mM	0.1388 mL	0.6940 mL	1.3881 mL	3.4702 mL
	25 mM	0.1110 mL	0.5552 mL	1.1105 mL	2.7762 mL
	30 mM	0.0925 mL	0.4627 mL	0.9254 mL	2.3135 mL
	40 mM	0.0694 mL	0.3470 mL	0.6940 mL	1.7351 mL
	50 mM	0.0555 mL	0.2776 mL	0.5552 mL	1.3881 mL
	60 mM	0.0463 mL	0.2313 mL	0.4627 mL	1.1567 mL
	80 mM	0.0347 mL	0.1735 mL	0.3470 mL	0.8675 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

PD153035 (Synonyms: SU-5271; AG1517; ZM 252868)

Customer Review

Other Forms of PD153035:

MCE 顾客使用本产品发表的 8 篇科研文献

PD153035 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 EGFR 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

PD153035 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

PD153035 (Synonyms: SU-5271; AG1517; ZM 252868)

Customer Review

Other Forms of PD153035:

PD153035 相关抗体

MCE 顾客使用本产品发表的 8 篇科研文献

PD153035 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 EGFR 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

PD153035 相关抗体:

摩尔计算器

稀释计算器

PD153035 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z